Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc study for Garenoxacin
2006-006168-46Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of garenoxacin in bacterial disease (3 arms), sponsored by Merck & Co. Primary endpoint: QT/QTc prolongation and proarrhythmic potential (Part 1 primary endpoint). Started Dec 2006; status: completed.
02
Drugs
garenoxacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2006-006168-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006168-46.